✨ Free AI Report
Upstream Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Upstream Bio, Inc.
Company Research

Upstream Bio, Inc.: Business Overview, Financials & Competitive Analysis

Upstream Bio, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). First-in-class TSLP antagonist with validated clinical efficacy, strong analyst backing, and significant market opportunity in respiratory diseases. Upstream Bio demonstrates strong fundamentals as a clinical-stage biotech with a differentiated, first-in-class mechanism targeting TSLP signaling. Recent positive Phase 2 asthma data (February 2026) and analyst support from major firms provide.

What is Upstream Bio, Inc.'s industry? Upstream Bio, Inc. (upstreambio.com) operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases. AskCyborg classifies Upstream Bio, Inc. under Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases in its company registry.

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for se...

7/ 10Strong

Cyborg Score thesis

First-in-class TSLP antagonist with validated clinical efficacy, strong analyst backing, and significant market opportunity in...

Read the full analyst-debate transcript →
Industry Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Upstream Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Upstream Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Upstream Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Upstream Bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Upstream Bio, Inc. Overview

Pro stress-test →

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase 1 trials for COPD. The company recently achieved a critical milestone with positive Phase 2 trial data in February 2026.

Strategic Profile

Pro stress-test →

Verekitug is the only known antagonist currently in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine positioned upstream of multiple signaling cascades affecting various immune-mediated diseases. This novel mechanism of action addresses significant unmet needs in respiratory inflammation treatment with potential applications beyond the initial respiratory disease focus.

Competitive Landscape

Pro stress-test →

Upstream Bio competes in the severe respiratory inflammation space against established therapies and newer biologics from larger pharma. The company's differentiated TSLP antagonism mechanism provides competitive advantages versus current standard-of-care asthma treatments and other emerging respiratory therapeutics, though success depends on Phase 2/3 trial progression.

Industry Context

Upstream Bio, Inc. operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases.

Key facts

Founded: 2021 · Headquarters: Waltham, Massachusetts · Market cap: $1.68B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Upstream Bio, Inc..

  • Recently announced positive Phase 2 VALIANT trial results for severe asthma treatment (February 11, 2026)
  • Analyst consensus is bullish with Piper Sandler maintaining Overweight rating and $75 price target; Mizuho Outperform with $51 target
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Positive Phase 2 VALIANT trial results for severe asthma with verekitug announced
  • February 2026Evercore ISI maintained Buy rating on the stock
  • +1 moreTrack every material event for Upstream Bio, Inc. as it happens. Explore monitoring →
Get alerted when Upstream Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupilumabIL-4R antagonist for moderate-to-severe asthma and atopic dermatitis→MepolizumabIL-5 antagonist for eosinophilic asthma→ReslizumabIL-4 antagonist for moderate-to-severe asthma→

Compare Upstream Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Upstream Bio, Inc. operates in Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Biotechnology - Respiratory/Inflammatory Diseases research →
NEW · MCP server

Ask your AI assistant about Upstream Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Upstream Bio, Inc. and its top competitor on Cyborg Score”
“What did Upstream Bio, Inc. do this quarter?”
“Is Upstream Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Upstream Bio, Inc. do?+
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases focusing on severe respiratory disorders, with its lead candidate verekitug in Phase 2 clinical development for se...
What is Upstream Bio, Inc.'s Cyborg Score?+
Upstream Bio, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Upstream Bio, Inc.'s main competitors?+
Named competitors include Dupilumab, Mepolizumab, Reslizumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Upstream Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Upstream Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Upstream Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.